Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 10/20 | 0.58 |
| ▸ | EGFR | P00533 | 8/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | GOT1 | P17174 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479267 | 0.82 | EGFR (0.76) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL31426459 | 0.82 | EGFR (0.76) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL4783313 | 0.82 | EGFR (0.58) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL13286756 | 0.79 | NPC1 (0.71) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL20356686 | 0.78 | EGFR (0.61) | SMN1; SMN2MAPTKDM4EMAPK1KMT2A | |
| SCHEMBL13304892 | 0.78 | GAA (0.47) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL13056966 | 0.77 | EGFR (0.59) | SMN1; SMN2MAPTNPC1RAB9AMEN1 | |
| SCHEMBL17083353 | 0.77 | EGFR (0.50) | KDREGFR | |
| SCHEMBL3759264 | 0.75 | EGFR (0.74) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL31060970 | 0.74 | KDR (1.00) | SMN1; SMN2MAPTKDRTP53PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO | 2006-09-28 | — | — | US | disclosed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | disclosed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | disclosed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | disclosed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | disclosed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | SMN1; SMN2 3093/4885MAPT 3847/4885KDM4E 1959/4885 |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, NR2E3, FLT1 | SMN1; SMN2 2321/4885MAPT 683/4885KDM4E 2355/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | SMN1; SMN2 3075/4885MAPT 632/4885KDM4E 2156/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | SMN1; SMN2 3971/4885MAPT 3648/4885KDM4E 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.